Multiple Intravenous Injections of Valproic Acid-Induced Mesenchymal Stem Cell from Human-Induced Pluripotent Stem Cells Improved Cardiac Function in an Acute Myocardial Infarction Rat Model

Figure 6

hiPSC-MSC administration improved the cardiac function. (a) LVEF of the PBS-injection group continued to decline from week 0 to week 12. hiPSC-MSC injection increased LVEF to different extents in cell-treated groups. (b) The improvement in LVEF in the hiPSC-MSC-injection groups was significant compared with that in the PBS-injection group at week 12 (PBS-injection group v. two-injection group, ; PBS-injection group v. four-injection group, ). There was a significant difference between the two-injection and the four-injection groups, . (c) LVFS of the PBS-injection group kept declining from week 0 to week 12. hiPSC-MSC treatments increased LVFS to different levels in the MSC-injection groups. (d) Significant differences were found when comparing the improvement extent of LVFS of the hiPSC-MSC-injection groups with that of the PBS-injection group at the end of week 12 (PBS-injection group v. two-injection group, ; PBS-injection group v. four-injection group, ). (e) In the PBS-injection group, LVEDD increased continuously over 12 weeks. hiPSC-MSC treatments prevented the increase of LVEDD in the hiPSC-MSC-injection groups to different levels compared with that of the PBS-injection group. (f) The differences of LVEDD prevention among the hiPSC-MSC-injection groups and the PBS-injection group were insignificant at the end of 12 weeks.

(a)

(b)

(c)

(d)

(e)

(f)